{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:21:25Z","timestamp":1791415285793,"version":"4.3.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"DOI":"10.7759\/cureus.54311","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T18:25:17Z","timestamp":1708107917000},"source":"Crossref","is-referenced-by-count":7,"title":["A Comparative Study of the Safety and Efficacy Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Management of Hypertension: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Tariladei S","family":"Peresuodei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chijioke","family":"Orji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiss","family":"Reghefaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michell Susan","family":"Saavedra Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuheen Sankar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Hypertension. (2023). Accessed. March 16, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009096.pub2","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li EC","year":"2014","unstructured":"Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014, CD009096. 10.1002\/14651858.CD009096.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3109\/10641969709083217","article-title":"Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension","volume":"19","author":"Bremner AD","year":"1997","unstructured":"Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997, 19:1263-85. 10.3109\/10641969709083217","journal-title":"Clin Exp Hypertens"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715120-00020","article-title":"24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring","volume":"15","author":"Fogari R","year":"1997","unstructured":"Fogari R, Ambrosoli S, Corradi L, et al.. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens. 1997, 15:1511-8. 10.1097\/00004872-199715120-00020","journal-title":"J Hypertens"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(01)80101-6","article-title":"Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension","volume":"1922","author":"Flack JM","year":"2001","unstructured":"Flack JM, Saunders E, Gradman A, et al.. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001, 1922:1193-208. 10.1016\/s0149-2918(01)80101-6","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317728766","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: systematic review and meta-analysis","volume":"24","author":"Salvador GL","year":"2017","unstructured":"Salvador GL, Marmentini VM, Cosmo WR, Junior EL. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: systematic review and meta-analysis. Eur J Prev Cardiol. 2017, 24:1914-24. 10.1177\/2047487317728766","journal-title":"Eur J Prev Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2008.02.025","article-title":"The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias","volume":"5","author":"Iravanian S","year":"2008","unstructured":"Iravanian S, Dudley SC Jr. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm. 2008, 5:S12-7. 10.1016\/j.hrthm.2008.02.025","journal-title":"Heart Rhythm"},{"key":"ref8","article-title":"Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension","volume":"42","author":"Akat PB","year":"2010","unstructured":"Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol. 2010, 42:153-6.","journal-title":"Indian J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001720","article-title":"Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis","volume":"36","author":"Xie W","year":"2018","unstructured":"Xie W, Zheng F, Evangelou E, et al.. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. J Hypertens. 2018, 36:1256-65. 10.1097\/HJH.0000000000001720","journal-title":"J Hypertens"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7292.977","article-title":"Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review","volume":"322","author":"Padwal R","year":"2001","unstructured":"Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ. 2001, 322:977-80. 10.1136\/bmj.322.7292.977","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1938-8","article-title":"Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information","volume":"27","author":"Powers BJ","year":"2012","unstructured":"Powers BJ, Coeytaux RR, Dolor RJ, et al.. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2012, 27:716-29. 10.1007\/s11606-011-1938-8","journal-title":"J Gen Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-1-200801010-00189","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension","volume":"148","author":"Matchar DB","year":"2008","unstructured":"Matchar DB, McCrory DC, Orlando LA, et al.. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008, 148:16-29. 10.7326\/0003-4819-148-1-200801010-00189","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000153308.91043.97","article-title":"Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus","volume":"45","author":"Rizzoni D","year":"2005","unstructured":"Rizzoni D, Porteri E, De Ciuceis C, et al.. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension. 2005, 45:659-65. 10.1161\/01.HYP.0000153308.91043.97","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett AH","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004, 351:1952-61. 10.1056\/NEJMoa042274","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00224.x","article-title":"Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy","volume":"58","author":"Lacourci\u00e8re Y","year":"2000","unstructured":"Lacourci\u00e8re Y, B\u00e9langer A, Godin C, Hall\u00e9 JP, Ross S, Wright N, Marion J. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000, 58:762-9. 10.1046\/j.1523-1755.2000.00224.x","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32833e116b","article-title":"Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study","volume":"28","author":"Malacco E","year":"2010","unstructured":"Malacco E, Omboni S, Volpe M, Auteri A, Zanchetti A. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens. 2010, 28:2342-50. 10.1097\/HJH.0b013e32833e116b","journal-title":"J Hypertens"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199905000-00007","article-title":"Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension","volume":"6","author":"Neutel JM","year":"1999","unstructured":"Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999, 6:161-6. 10.1097\/00045391-199905000-00007","journal-title":"Am J Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/08037050152669747","article-title":"Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial","volume":"10","author":"Ruilope L","year":"2001","unstructured":"Ruilope L, J\u00e4ger B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. 2001, 10:223-9. 10.1080\/08037050152669747","journal-title":"Blood Press"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.25.6.1345","article-title":"A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension","volume":"25","author":"Gradman AH","year":"1995","unstructured":"Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995, 25:1345-50. 10.1161\/01.hyp.25.6.1345","journal-title":"Hypertension"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000482","article-title":"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril","volume":"11","author":"Black HR","year":"1997","unstructured":"Black HR, Graff A, Shute D, et al.. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997, 11:483-9. 10.1038\/sj.jhh.1000482","journal-title":"J Hum Hypertens"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James PA","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al.. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014, 311:507-20. 10.1001\/jama.2013.284427","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001964","article-title":"Effect of telmisartan\/hydrochlorothiazide vs lisinopril\/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients","volume":"20","author":"Fogari R","year":"2006","unstructured":"Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of telmisartan\/hydrochlorothiazide vs lisinopril\/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006, 20:177-85. 10.1038\/sj.jhh.1001964","journal-title":"J Hum Hypertens"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199917020-00015","article-title":"Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group","volume":"17","author":"Karlberg BE","year":"1999","unstructured":"Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999, 17:293-302. 10.1097\/00004872-199917020-00015","journal-title":"J Hypertens"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000997","article-title":"Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients","volume":"14","author":"McInnes GT","year":"2000","unstructured":"McInnes GT, O'Kane KP, Istad H, Kein\u00e4nen-Kiukaanniemi S, Van Mierlo HF. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000, 14:263-9. 10.1038\/sj.jhh.1000997","journal-title":"J Hum Hypertens"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000489913","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis","volume":"43","author":"Wang K","year":"2018","unstructured":"Wang K, Hu J, Luo T, et al.. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018, 43:768-79. 10.1159\/000489913","journal-title":"Kidney Blood Press Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010256","article-title":"Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis","volume":"97","author":"Lv X","year":"2018","unstructured":"Lv X, Zhang Y, Niu Y, Song Q, Zhao Q. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e0256. 10.1097\/MD.0000000000010256","journal-title":"Medicine (Baltimore)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415619490","article-title":"Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Chaugai S","year":"2016","unstructured":"Chaugai S, Meng WY, Ali Sepehry A. Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2016, 21:388-404. 10.1177\/1074248415619490","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003822.pub2","article-title":"Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension","author":"Heran BS","year":"2008","unstructured":"Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008, CD003822. 10.1002\/14651858.CD003822.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003823.pub2","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","author":"Heran BS","year":"2008","unstructured":"Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008, CD003823. 10.1002\/14651858.CD003823.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/196928-a-comparative-study-of-the-safety-and-efficacy-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-on-the-management-of-hypertension-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T18:25:20Z","timestamp":1708107920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/196928-a-comparative-study-of-the-safety-and-efficacy-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-on-the-management-of-hypertension-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.54311","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}